BRAF V600E (and V600K) in cutaneous melanoma is the prototypical driver: combination BRAF...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-MELANOMA |
| ESCAT tier | IA |
| Recommended combinations | dabrafenib + trametinib, encorafenib + binimetinib, vemurafenib + cobimetinib, atezolizumab + vemurafenib + cobimetinib (triplet) |
| Contraindicated monotherapy | BRAFi monotherapy (vemurafenib alone) — inferior OS vs combo, paradoxical RAS/RAF activation in BRAF-WT clones |
| Evidence summary | BRAF V600E (and V600K) in cutaneous melanoma is the prototypical driver: combination BRAF + MEK inhibition (dabrafenib + trametinib; encorafenib + binimetinib; vemurafenib + cobimetinib) yields high ORR (~65-70%) and improves OS vs single-agent BRAFi (COMBI-d/v, coBRIM, COLUMBUS). Adjuvant dabrafenib + trametinib improves RFS in resected stage III (COMBI-AD). Triplet with anti-PD-1 (atezolizumab + vemurafenib + cobimetinib; IMspire150) extends PFS over doublet. |
Notes
ESCAT IA per ESMO precision-medicine WG. OncoKB Level 1. Companion diagnostics: cobas 4800 BRAF V600 Mutation Test, THxID-BRAF, FoundationOne CDx. V600K behaves clinically like V600E (slightly lower response rates) and shares all approvals.
Used By
No reverse references found in the YAML corpus.